Free Trial
NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

Illumina logo
$95.41 +0.62 (+0.65%)
As of 06/30/2025 04:00 PM Eastern

About Illumina Stock (NASDAQ:ILMN)

Key Stats

Today's Range
$94.16
$96.83
50-Day Range
$74.35
$95.41
52-Week Range
$68.70
$156.66
Volume
1.85 million shs
Average Volume
2.14 million shs
Market Capitalization
$15.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$127.39
Consensus Rating
Hold

Company Overview

Illumina, Inc. is a leading developer, manufacturer and marketer of life science tools and integrated systems for large‐scale analysis of genetic variation and function. Founded in 1998 and headquartered in San Diego, California, the company pioneered next-generation sequencing (NGS) technology that has accelerated research in genomics and transformed applications in diagnostics, agriculture and drug development. Its flagship platforms include the NovaSeq, NextSeq and MiSeq systems, which enable high-throughput sequencing for whole-genome, exome and targeted panels.

In addition to sequencing instruments, Illumina offers a broad portfolio of microarray products, consumables, software and services designed to support diverse workflows from sample preparation through data analysis. The company’s reagent kits and flow cells ensure high accuracy and reproducibility, while its BaseSpace Sequence Hub provides a cloud-based environment for data management, secondary analysis and collaboration. These integrated solutions serve customers in academic institutions, clinical laboratories, pharmaceutical companies and agricultural research centers worldwide.

Illumina’s technologies have underpinned major scientific projects such as the Human Genome Project follow-on studies, large-scale population genomics initiatives and precision medicine programs. By enabling rapid, cost-effective genomic data generation, the company has opened new avenues in oncology, prenatal testing, rare disease research and microbial genomics. Collaborations with leading healthcare providers and research consortia further extend the reach of its diagnostic and therapeutic applications.

Governed by a seasoned leadership team and board of directors, Illumina is led by President and Chief Executive Officer Francis deSouza, who has guided the company through significant product launches and strategic partnerships. With operational centers in North America, Europe and Asia-Pacific, Illumina maintains a global footprint that supports local market needs while fostering innovation through regional R&D hubs. The company continues to invest in expanding its technological capabilities to address emerging challenges in genomics and personalized medicine.

AI Generated. May Contain Errors.

Illumina Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

ILMN MarketRank™: 

Illumina scored higher than 97% of companies evaluated by MarketBeat, and ranked 41st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Illumina has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 8 buy ratings, 9 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Illumina has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Illumina's stock forecast and price target.
  • Earnings Growth

    Earnings for Illumina are expected to grow by 14.41% in the coming year, from $4.51 to $5.16 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Illumina is -15.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Illumina is -15.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Illumina has a PEG Ratio of 1.86. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Illumina has a P/B Ratio of 6.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Illumina's valuation and earnings.
  • Percentage of Shares Shorted

    4.09% of the float of Illumina has been sold short.
  • Short Interest Ratio / Days to Cover

    Illumina has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Illumina has recently increased by 14.96%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Illumina does not currently pay a dividend.

  • Dividend Growth

    Illumina does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.09% of the float of Illumina has been sold short.
  • Short Interest Ratio / Days to Cover

    Illumina has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Illumina has recently increased by 14.96%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Illumina has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 29 news articles for Illumina this week, compared to 18 articles on an average week.
  • Search Interest

    Only 15 people have searched for ILMN on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Illumina insiders have bought more of their company's stock than they have sold. Specifically, they have bought $495,381.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.17% of the stock of Illumina is held by insiders.

  • Percentage Held by Institutions

    89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Illumina's insider trading history.
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Stock News Headlines

This Crypto Is Set to Explode in January
Free summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this means and how everyday investors like you can position themselves to potentially profit. The timing couldn't be more critical
Illumina, Inc. (ILMN): A Bull Case Theory
See More Headlines

ILMN Stock Analysis - Frequently Asked Questions

Illumina's stock was trading at $133.63 at the start of the year. Since then, ILMN shares have decreased by 28.6% and is now trading at $95.41.
View the best growth stocks for 2025 here
.

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings results on Thursday, May, 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. The firm's quarterly revenue was down 1.4% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Illumina: Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and others.

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/08/2025
Today
6/30/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ILMN
Employees
9,030
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$127.39
High Stock Price Target
$200.00
Low Stock Price Target
$85.00
Potential Upside/Downside
+33.5%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
19 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
21.16
P/E Growth
1.86
Net Income
-$1.22 billion
Pretax Margin
-20.48%

Debt

Sales & Book Value

Annual Sales
$4.37 billion
Cash Flow
$4.72 per share
Price / Cash Flow
20.21
Book Value
$14.96 per share
Price / Book
6.38

Miscellaneous

Free Float
158,031,000
Market Cap
$15.10 billion
Optionable
Optionable
Beta
1.33

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ILMN) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners